Ophthalmic optogenetics company raises $6M in funding

Biopharmaceutical company RetroSense Therapeutics (Ann Arbor, MI) has secured $6 million in Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.

Related: Optogenetics tools address a growing range of applications

Earlier in 2015, the company closed $7 million in Series A financing, bringing the total Series A and Series B investment to $13 million. Total net proceeds should enable completion of the company’s recently initiated Phase I/II clinical study for its lead compound, RST-001, for treatment of retinitis pigmentosa, a genetic condition that leads to the progressive degeneration of rod and cone photoreceptors and eventually results in severe vision loss and blindness. The funding will also support the further development of a second promising gene therapy candidate.

The FDA granted Orphan Drug Designation to RST-001 in 2014 and authorized first-in-human clinical trials for the product in 2015. Recruitment for the Phase I/II clinical study (NCT02556736) is currently underway. RST-001 is expected to have application to all forms of retinitis pigmentosa, independent of an individual’s causative gene or mutation. RST-001 is being developed as a first-in-class gene therapy application of optogenetics designed to restore vision to those affected by retinal degenerative conditions.

For more information, please visit www.retro-sense.com.

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

FDA authorizes emergency use of Zika virus molecular detection assay

The xMAP MultiFLEX Zika RNA assay combines optofluidics and digital signal processing to detect Zika virus in vitro.

'Lab on a stick' test optically and rapidly detects antibiotic resistance

A point-of-care test, based on the dipstick method, can rapidly detect bacterial resistance to antibiotics in urine.

Shortwave-infrared device could improve ear infection diagnosis

An otoscope-like device that could improve ear infection diagnosis uses shortwave-infrared light instead of visible light.

Microscope detects one million-plus biomarkers for sepsis in 30 minutes

A microscope has the potential to simultaneously detect more than one million biomarkers for sepsis at the point of care.

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS